Financial Performance - Operating revenue for the reporting period was ¥382,386,740.12, down 4.33% compared to the same period last year[8] - Net profit attributable to shareholders of the listed company was ¥30,863,884.29, a decrease of 43.43% year-on-year[8] - Basic earnings per share for the reporting period was ¥0.51, down 43.43% compared to the same period last year[8] - The weighted average return on net assets was 3.48%, a decrease of 56.26% year-on-year[8] - The company reported a decrease in net profit excluding non-recurring gains and losses, which was ¥28,796,023.06, down 40.05% year-on-year[8] - Total operating revenue for Q3 2019 was CNY 382,386,740.12, a decrease of 4.3% compared to CNY 399,703,109.15 in the same period last year[46] - Operating profit for the period was CNY 35,481,528.20, down 41.1% from CNY 60,103,388.17 in Q3 2018[48] - Net profit for Q3 2019 was CNY 30,863,884.29, a decline of 43.4% compared to CNY 54,560,353.00 in the previous year[48] - Total comprehensive income for the period was CNY 33,489,437.08, a decrease of 45.5% from CNY 61,416,869.77 in Q3 2018[50] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,587,498,702.71, an increase of 67.63% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company amounted to ¥1,924,748,226.95, reflecting a 145.49% increase year-on-year[8] - The company's total assets reached ¥2,587,498,702.71, up from ¥1,543,575,535.19, reflecting a robust growth in both current and non-current assets[35] - Total liabilities decreased from CNY 759,530,213.52 to CNY 662,750,475.76, a reduction of approximately 12.76%[39] - Owner's equity increased significantly from CNY 784,045,321.67 to CNY 1,924,748,226.95, representing a growth of about 145.06%[39] - Current assets rose from CNY 541,798,766.86 to CNY 1,624,761,349.35, an increase of approximately 199.63%[42] - Total assets amounted to CNY 2,312,312,626.02, an increase from CNY 1,229,550,814.83 year-on-year[46] - Total liabilities and owners' equity reached CNY 2,312,312,626.02, reflecting a significant growth compared to CNY 1,229,550,814.83 in the previous year[46] Cash Flow - Cash flow from operating activities for the year-to-date was ¥193,186,287.82, an increase of 37.18% compared to the same period last year[8] - Cash paid for taxes decreased by 31.40% to ¥50,411,822.54, influenced by a reduction in VAT rates and changes in pre-paid corporate income tax rates[25] - Cash outflow for the purchase of fixed assets and other long-term assets decreased by 43.14% to ¥108,603,703.83, compared to ¥191,009,581.20 in the previous year, due to reduced investment in the first phase of the Ma'anshan production base[25] - The ending balance of cash and cash equivalents was ¥1,033,610,987.82, up from ¥44,491,359.28 in the previous period[72] - Total cash inflow from financing activities reached ¥1,188,361,320.75, significantly higher than ¥130,665,845.64 in the previous period[72] Shareholder Activities - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[20] - The company reported a 68.83% decrease in cash paid for dividends and interest, amounting to ¥11,851,391.13, primarily due to dividend payments made in 2018[25] Research and Development - Research and development expenses were CNY 16,355,015.32, slightly down from CNY 17,189,576.75 in the same period last year[46] - Research and development expenses increased to CNY 43.68 million, up 9.5% from CNY 39.77 million in the previous year[62] Financial Management - Financial expenses increased by 40.86% to ¥9,497,531.15, mainly due to higher interest expenses[24] - The company’s financial expenses decreased to CNY 3.82 million, down from CNY 4.25 million in the previous year[62] Other Information - The company did not undergo an audit for the third quarter report[73] - The company has not applied new financial instrument standards or new revenue standards for the current reporting period[73]
仙乐健康(300791) - 2019 Q3 - 季度财报